为什么对血友病的基因治疗的接受率低于预期?
Glenn F Pierce1, Mark Skinner1,2,3, Brian O'Mahony1,4
1World Federation of Hemophilia, Montreal, Quebec, Canada.
Research and practice in thrombosis and haemostasis
|July 25, 2025
概括
血友病的基因疗法显示出希望,在因子IX治疗中取得了一些成功,实现了功能治愈. 然而,基因相关病毒载体的挑战和高成本阻碍了因子VIII和FIX基因疗法的广泛采用.
科学领域:
- 血液学 血液学 血液学
- 基因治疗 基因治疗
- 病毒载体 病毒载体
背景情况:
- 血友病 (FVIII和FIX) 的基因疗法已经被探索了40多年.
- 腺相关病毒 (AAV) 载体占主导地位,但在有效性和安全性方面面临挑战.
- 临床研究的结果各不相同,有些人未能支持商业用途.
相关概念视频
Gene Therapy
25.9K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.9K
Microorganisms in Medicine and Therapeutics
345
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
345


